Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn study - PubMed
5 hours ago
- #secukinumab
- #early intervention
- #psoriasis
- The STEPIn study evaluated early intervention with secukinumab in patients with new-onset plaque psoriasis (≤1 year disease duration).
- At week 104 (one year after treatment withdrawal at week 52), 20.8% of secukinumab-treated patients sustained a PASI 90 response, with 44% not relapsing during the treatment-free period.
- The study concluded that early secukinumab intervention maintains efficacy in a subset of patients one year after withdrawal, though limitations include its open-label design.